share_log

天坛生物(600161.SH):注射用重组人凝血因子Ⅷ-Fc融合蛋白获得药物临床试验批准通知书

Tiantan Biology (600161.SH): Injecting recombinant human coagulation factor VIII-Fc fusion protein obtained a drug clinical trial approval notice

Gelonghui Finance ·  Dec 22, 2023 06:51

Gelonghui, December 22|Tiantan Biotech (600161.SH) announced that recently, Chengdu Rongsheng Pharmaceutical Co., Ltd., a subsidiary of Beijing Tiantan Biological Products Co., Ltd., obtained the “Notice of Approval of Drug Clinical Trials” issued by the State Drug Administration, agreeing that Chengdu Rongsheng will conduct a clinical trial of “injectable recombinant human coagulation factor-FC fusion protein” according to the submitted plan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment